Thrombosis research
-
Thrombosis research · Jan 2007
Pre-admission warfarin use in patients with acute ischemic stroke and atrial fibrillation: The appropriate use and barriers to oral anticoagulant therapy.
Warfarin reduces the risk of stroke in patients with atrial fibrillation. Despite strong guideline recommendations, studies continue to demonstrate the under-use of warfarin in clinical practice. ⋯ early half of all patients presenting with atrial fibrillation and acute ischemic stroke who were suitable candidates for anticoagulation were not prescribed warfarin. In patients not prescribed warfarin, very few had a documented contraindication. Advanced age appears to be the strongest predictor of warfarin non-use.
-
Thrombosis research · Jan 2007
Clinical TrialThe respective and combined anticoagulant effects of recombinant human activated protein C, melagatran and heparins using CAT.
Combinations of anticoagulants might be beneficial in some patients with sepsis, but most anticoagulants require specific clotting assays for monitoring. Thrombin generation assay, however, is a global function test of hemostasis. ⋯ In our in vitro study adding either melagatran, UH or LMWH augmented the capacity of rhAPC to suppress thrombin generation in human plasma. These findings suggest that patients with severe sepsis might benefit from a treatment with combinations of anticoagulant agents.
-
Thrombosis research · Jan 2007
A novel intermittent mechanical compression device for stasis prevention in the lower limbs during limited mobility situations.
Intermittent pneumatic mechanical compression is commonly applied to obviate venous stasis in patients with increased risk of thromboembolism. Aviafit is a small battery-operated intermittent compression device using a patented mechanical, non-pneumatic technology. Our objective was to examine its ability to prevent venous stasis. ⋯ The lightweight, battery-operated and user-friendly Aviafit can provide the same hemodynamic benefits as larger conventional intermittent pneumatic compression devices. Its potential advantages for prophylaxis of thromboembolism and increased compliance in rehabilitation and homecare, and for use during long periods of immobility such as during flights, are evident.
-
Our aim was to study the association between the level of D-dimer and the severity of pulmonary embolism (PE) as determined by various biochemical and radiological prognostic markers in order to investigate the potential value of D-dimer as a prognostic marker for the severity of PE. ⋯ We have shown that the level of D-dimer is related to the severity of PE assessed by various radiological, biochemical and clinical markers and might have a potential value as prognostic marker for the severity of PE.
-
Thrombosis research · Jan 2007
Cinnamaldehyde reduction of platelet aggregation and thrombosis in rodents.
Cinnamaldehyde (CA) has been reported to inhibit in vitro aggregation in human and rabbit platelets; however, little is known about the antithrombotic activities of CA in vivo. ⋯ The results demonstrate that CA may be a promising antithrombotic agent, and its antithrombotic activity may be due to anti-platelet aggregation activity in vitro and in vivo.